A Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. patent describes new probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors potentially useful for the treatment of cancer.
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as potentially useful for the treatment of epilepsy, schizophrenia, autism, cancer, mood disorder, sepsis, Alzheimer’s disease and vascular disorders, among others.
Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.
Work at Khartis Therapeutics Inc. has led to the discovery of new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves ophthalmopathy), age-related macular degeneration, idiopathic orbital inflammatory disease, cancer and inflammatory disorders.
Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed new compounds targeting apolipoprotein A (ApoA; LPA) and acting as lipoprotein(a)-lowering agents that are potentially useful for the treatment of cardiovascular disorders.
Emory University has divulged new prostaglandin EP2 receptor (PTGER2) antagonists potentially useful for the treatment of cancer, neuropathic pain, hypertension, inflammatory bowel disease, Alzheimer’s disease, atherosclerosis, asthma and glomerulonephritis, among others.
Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has discovered new prodrugs of glucagon-like peptide 1 (GLP-1) polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, overweight, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, neurodegeneration, diabetic nephropathy and cardiovascular disorders, among others.
RSS